Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada

Vaccine

Volumn 30, Issue 2, 2012, Pages 425-435

  Tully, Stephen P ^a   Anonychuk, Andrea M ^b,c   Maria Sanchez, Diana ^d   Galvani, Alison P ^d   Bauch, Chris T ^a,e  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d YALE UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Catch up immunization; Cervical cancer; Cervical screening; Cost utility analysis; Dynamic model; Human papillomavirus vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CANCER SCREENING; COST UTILITY ANALYSIS; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS IMMUNIZATION; HUMAN PAPILLOMAVIRUS TYPE 11; IMMUNIZATION; MALE; MODEL; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CANADA; COST-BENEFIT ANALYSIS; CROSS PROTECTION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84355162819     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.067     Document Type: Article

References (91)

1. Sanjose S., Diaz M., Castellsague X., Cliffofrd G., Bruni L., Munoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
2. Vizcaino A., Moreno V., Bosch F., Munoz N., Barros-Dios Z., Borras J., et al. International trends in incidence of cervical cancer. II. Squamous-cell carcinoma. Int J Cancer 2000, 86:429-435.
3. Canadian Cancer Statistics 2009 Special topic: cancer in adolescents and young adults 2009, Canadian Cancer Society, Toronto.
4. van de Velde N., Brisson M., Boily M. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007, 165(7):762-775.
5. Canadian Cancer Society. Canadian Cancer Statistics. Toronto, ON; 2011.
6. Programmatic guidelines for screening for cancer of the cervix in Canada 1998, Society of Gynecologic Oncologists of Canada.
7. Cervical cancer screening in Canada: 1998 surveillance report 2002, Health Canada, http://www.phac-aspc.gc.ca/publicat/ccsic-dccuac/index-eng.php.
8. Durst M., Gissmann L., Ikenberg H., zurHausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983, 80:3812-3815.
9. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87(11):796-802.
10. Paavonen J., Naud P., Salmeron J., Wheeler C., Chow S., Apter D. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by onogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
11. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278.
12. Bauch C.T., Li M., Chapman G., Galvani A.P. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?. Lancet Infect Dis 2010, 10:133-137.
13. Garnett G.P., Kim J.J., French K., Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(SUPPL. 3):S178-S186.
14. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3(5):624-632.
15. Hughes J.P., Garnett G.P., Koutsky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology 2002, 13(6):631-639.
16. Dasbach E., Elbasha E., Insinga R. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and diseases. Epidemiol Rev 2006, 28(1):88-100.
17. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
18. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., Franco E. A comphrehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106:896-904.
19. Burchell A., Richardson H., Mahmud S. Modeling the sexual transmissibility of HPV infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006, 163(6):534-543.
20. Brisson M., van de Velde N., Boily M.C., de Wals P. Estimating the number needed to vaccinate to prevent HPV related disease and mortality. Can Med Assoc J 2007, 177:464-468.
21. Brisson M., van de Velde N., de Wals P., Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25(29):5399-5408.
22. Anonychuk A.M., Bauch C.T., Merid M.F., VanKriekinge G., Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009, 9:401.
23. Van de Velde N., Brisson M., Boily M. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(33):5473-5484.
24. Usher C., Tilson L., Olsen J., Jepsen M., Walsh C., Barry M. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 2008, 26:5654-5661.
25. Newall A.T., Beutels P., Wood J.G., Edmunds W.J., MacIntyre C. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007, 7(4):289-296.
26. Torvinen S., Nieminen P., Lehtinen M., Paavonen J., Demarteau N., Hahl J. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 2010, 13(2):284-294.
27. Muller H., Bauch C.T. When do sexual partnerships need to be accounted for in transmission models of human papillomavirus?. Int J Environ Res Public Health 2010, 7(2):635-650.
28. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005, 191:S97-S106.
29. Marra F., Cloutier K., Oteng B., Marra C., Ogilvie G. Effectiveness and cost-effectivenes of human papillomavirus vaccine: a systematic review. PharmacoEconomics 2009, 27(2):127-147.
30. Elbasha E.H., Dasbach E.J., Insinga R.P., Haupt R.M., Barr E. Age-based programs for vaccination against HPV. Value Health 2009, 12(5):697-707.
31. Debicki D., Ferko N., Demarteau N., Gallivan S., Bauch C., Anonychuk A., et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008, 15:F16-F28.
32. Olsen J., Jepsen M.R. Human papillomavirus transmission and cost-effectivness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010, 26:183-191.
33. Elbasha E.H., Galvani A.P. Vaccination against multiple HPV types. Math Biosci 2005, 197:88-117.
34. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. New Engl J Med 2008, 359:821-832.
35. Jit M., Demarteau N., Elbasha E., Ginsberg G., Kim J., Praditsitthikorn N., et al. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 2011, 9:54.
36. Kim J.J., Ortendahl J., Goldie S.J. Cost-effectiveness of HPV vaccination and cervical cancer screening in women over age 30 in the United States. Ann Intern Med 2009, 151(8):538-545.
37. Armstrong E.P. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 2010, 16(3):217-230.
38. Westra T.A., Rozenbaum M.H., Rogoza R.M., Nijman H.W., Daemen T., Postma M.J., et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 2011, 204(3):377-384.
39. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
40. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in health women aged 18-45 years. Human Vaccines 2009, 5(10):705-719.
41. Jones N. HPV protection in older groups may be in the eye of the beholder. Nat Med 2011, 17(6):637.
42. Bornstein J. The HPV vaccines-which to prefer?. Obstet Gynecol Surv 2009, 64(5):345-350.
43. Edmunds W., Medley G., Nokes D. Evaluating the cost-effectiveness of vaccination programs: a dynamic perspective. Stat Med 1999, 18(23):3263-3282.
44. Brisson M., Edmunds W. Economic evaluation of vaccination programs: the impact of herd immunity. Med Decis Making 2003, 23(1):76-82.
45. Drolet M., Brisson M., Maunsell E., Ferenczy A., Franco E.L., Ratnam S., et al. Quality of life lost following an abnormal cervical cytology result: a prospective 3-month study. Eurogin 2010 congress 2010.
46. Insinga R., Glass A., Rush B. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004, 191:105-113.
47. Taira A., Neukermans C., Sanders G. Evaluating human papillomavirus programmes. Emerg Infect Dis 2004, 10(11):1915-1923.
48. Ho G., Studentsov Y., Bierman R., Burk R. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004, 13:110-116.
49. Carter J., Koutsky L., Wipf G. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996, 174:927.
50. Dunne E.F. Prevalence of HPV infection among females in the United States. JAMA 2006, 297(8):813-819.
51. Viscidi R., Schiffman M., Hildesheim A., Herrero R., Castle P., Bratti M. Seroreactivity to human papillomavirus (HPV) types 16, 18 or 31 and risk of subsequent HPV infection. Cancer Epidemiol Biomarkers Prev 2004, 13:324.
52. StatCan Statistics Canada Website, Canadian Statistics Section, Vital Statistics 2007, http://www.statcan.ca.
53. CIHI Health indicators 2009 2009, Canadian Institute for Health Information, Ottawa, ON.
54. Webpage Cervical cancer-survival statistics 2010, Cancer Research UK, [June 18, 2010], Available from: http://info.cancerresearchuk.org/cancerstats/types/cervix/survival/index.htm.
55. Davey C. 2003 CytoBase report, Ammended [sic] 2003, INSCYTE Corporation, Toronto, Ontario.
56. Mayrand M., Duarte-Franco E., Rodrigues I., Walter S., Hanley J., Ferenczy A. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
57. Fahey M., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995, 141:680-689.
58. Karnon J., Peters J., Platt J., Chilcott J., McGoogan E., Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004, 8(20):3-78.
59. Lier D., Jacobs P. An economic analysis of the introduction of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in Alberta. A report for the Alberta cervical cancer screening program 2005.
60. Pretet J., Jacquard A., Carcopino X., Charlot J., Bouhour D., Kantelip B., et al. Human papillomavirus genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 2008, 122:428-432.
61. Pretet J., Jacquard A., Saunier M., Clavel C., Dachez R., Gondry K., et al. Human papillomavirus genotype distribution in low grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDITH III study. Gynecol Oncol 2008, 110:179-184.
62. Paavonen J., Jenkins D., Bosch X.F. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(9580):2161-2170.
63. Krahn M., McLachlin M., Pham B., Rosen B. Liquid-based techniques for cervical ccancer screening: systematic review and cost-effectiveness analysis. CADTH study report 2007.
64. Marcus A., Kaplan C., Crane L., Berek J., Bernstein G., Gunning G., et al. Reducing loss-to-follow-up among women with abnormal Pap smears; results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care 1998, 36(3):397-410.
65. McLachlin C.M., Fung M.F.K., Chambers A. Cervical screening: a clinical practice guideline 2005, Cervical Cancer Screening Guidelines Committee of the Ontario Cervical Cancer Screening Program and the Gynecology Cancer Disease Site Group of Cancer Care Ontario Evidence-based Series: Section 1.
66. Wagner E., Duggan M. Effectiveness of follow up-letters to health care providers in triggering follow-up for women with abnormal results on Papanicolaou testing. Can Med Assoc J 2001, 164(2):207-208.
67. Kahn J., Goodman E., Huan B., Slpa G., Emans S. Predictors of Papanicolau smear return in a hospital-based adolescent and young adult clinic. Obstet Gynecol 2003, 101(3):490-499.
68. Maxwell G., Carlson J., Ochoa M., Krivak T., Rose G., Myers E. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol 2002, 100(4):740-748.
69. Bauch C.T., Anonychuk A.M., Pham B.Z., Gilca V., Duval B., Krahn M.D. Cost-utility of universal hepatitis A vaccination in canada. Vaccine 2007, 25(51):8536-8548.
70. Mittman N., Trakas K., Risebrough N. Utility score for chronic conditions in a community-dwelling population. PharmacoEconomics 1999, 15:369-376.
71. Darroch J.E., Landry D.J., Oslak S. Age differences between sexual partners in the United States. Fam Plan Perspect 1999, 31(4):160-167.
72. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselbad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132(10):810-819.
73. Karnon J., Peters J., Platt J., Chilcott J., McGoogan E., Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004, 8(20):1-78.
74. Insinga R.P., Glass A.G., Myers E.R., Rush B.B. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007, 27(4):414-422.
75. Munoz N., Bosch F.X., Castellsague X., Diaz M., deSanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278-285.
76. Hirschler B. Glaxo cuts cervarix price by 30 pct in Canada 2010, http://www.reuters.com/article/2010/10/25/glaxo-cervarix-idCALDE69O10P20101025.
77. Kreimer A., Katki H., Schiffman M., Wheeler C., Castle P. Viral determinants of human papillomavirus persistence following loop electrical excision procedure for treatment of Cervical Intraepithelial Neoplasia Grade 2 or 3. Cancer Epidemiol Biomarkers Prev 2007, 16:11-16.
78. Council of Ministers of Education Canada Canadian youth, sexual health and HIV/AIDS study: factors influencing knowledge, attitudes and behaviours 2003.
79. Kretzschmar M. Sexual Network Structure and Sexually Transmitted Disease Prevention: A Modeling Perspective. Sexually Transmitted Diseases. 2000, 27(10):627-635.
80. Foxman B., Newman M., Percha B., Holmes K.K., Aral S.O. Measures of sexual partnerships: lengths, gaps, overlaps and sexually transmitted infection. Sex Transm Dis 2006, 33(4):209-214.
81. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765.
82. Rahbar-Rowhani A., Mao C., Alvarez F.B., Bryan J.T., Hawes S.E., Hughes J.P. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. Abstract book of the 25th international papillomavirus conference 2009, 29:3.
83. Krahn M., Guasparini R., Sherman M. Costs and cost-effectiveness of a universal school-based, adolescent hepatitis B vaccination program. Am J Public Health 1998, 88:1638-1644.
84. Guay M., Clouatre A., Blackburn M., Baron G., Wals P.D., Roy C. Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren. Can J Public Health 2003, 94(1):64-67.
85. Guay M., Blackburn M., Clement P., Tremblay A., St-Hilaire C., Clouatre A. Etude sur les couts et l'efficacite du programme de vaccination des enfants de 0-2 ans au Quebec: 2006, Institut national de sante publique du Quebec.
86. Gold M.R., Siegel J.E., Weinstein M.C. Cost-effectiveness in health and medicine. 2001, Oxford University Press, Oxford, UK.
87. Colucci R., Hryniuk W., Savage C. HPV vaccination programs in Canada: are we hitting the mark?. Report card on cancer in Canada 2008, 7-10.
88. Laupacis A., Feeny D., Detsky A., Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tenative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992, 146:473-481.
89. Lenselink C., Melchers W., Quint W., Hoebers A., Hendriks J., Massuger L., et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS ONE 2008, 3(11):e3743.
90. Sauvageau C., Duval B., Gilca V., Lavoie F., Ouakki M. Human papillomavirus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007, 7:304.
91. Bauch C.T., Rand D.A. A moment closure model for sexually transmitted disease spread through a concurrent partnership network. Proc R Soc Lond B 2000, 267:2019-2027.